Perspectives in the treatment of lung cancer: analysis of signaling pathways and biomarkers

Authors

DOI:

https://doi.org/10.33448/rsd-v11i7.22903

Keywords:

Non-small cell lung cancer; Tumor markers; Biological therapy.

Abstract

Lung cancer has the highest incidence and the highest mortality rate in the world. Precision medicine has significantly improved therapeutic options, increasing survival rates. However, a significant number of patients are not eligible for targeted therapies. Thus, molecular characterization and definition of gene signatures based on pathway enrichment can be essential for clinical management and understanding of the therapeutic plan. The objective is to define molecular signatures, enriched pathways and biomarkers of non-small cell lung cancer (NSCLC), outlining a molecular panel of gene expression. The bibliographic study performed was a quick review, with searches in the Latin American and Caribbean Literature in Health Sciences (LILACS) and Scientific Electronic Library Online (SciELO) electronic databases, using the descriptors "lung cancer", “molecular signatures”, “enrichment of pathways” and “neoplastic biomarkers”. Therefore, it was possible to identify differentially expressed genes and their inscription in possible signaling pathways, which can be important therapeutic targets.

References

Araujo, Luiz Henrique et al. Lungcancer in Brazil. J. bras. pneumol., São Paulo , v. 44, n. 1, p. 55-64, Feb. 2018 .

Brambilla, E.; Gazdar, A. Pathogenesis of lung cancer signalling pathways: roadmap for therapies. EuropeanRespiratoryJournal, v. 33, n. 6, p. 1485-1497, 2009.

Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2018;00(00):1–31.

Capelozzi, Vera luiza. Entendendo o papel de marcadores biológicos no câncer de pulmão. J. Pneumologia, São Paulo, v. 27, n. 6, p. 321-328, Nov. 2001.

Castro Junior, Gilberto de; Harada, Guilherme; Mello, Evandro Sobroza de. A importância da caracterização molecular no câncer de pulmão. J. bras. pneumol., São Paulo, v. 45, n. 3, e20190139, 2019.

Duan M, Zhong X, Liu G, Wei J. The Treg / Th17 Paradigm in Lung Cancer. 2014;2014.

Freitas, Claudia Sondermann. Estendendo o Conhecimento sobre a Família Her-Receptores para o Fator de Crescimento Epidérmico e seus ligantes às Malignidades Hematológicas. Revista brasileira de Cancerologia, v. 54, n. 1, p. 79-86, 2008.

Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26(3):317–25

Hamel C, et al. Defining Rapid Reviews: a systematic scoping review and thematic analysis of definitions and defining characteristics of rapid reviews. J Clin Epidemiol. 2020;129:74- 85. doi: http://doi.org/10.1016/j.jclinepi.2020.09.041

HILEY, Crispin T. et al. Challenges in molecular testing in non-small-celllungcancerpatientswithadvanceddisease. The Lancet, v. 388, n. 10048, p. 1002-1011, 2016.

JEMAL, Ahmedin et al. Global cancer statistics. CA: a cancer journal for clinicians, v. 61, n. 2, p. 69-90, 2011.

Kumar, Vinay; Abbas, Abul K.; Aster, Jon C. Robbins patologia básica. 9. ed. Rio de Janeiro: Elsevier, 2013.

Leal, L.F., de Paula, F.E., De Marchi, P. et al. Mutational profile ofBrazilianlungadenocarcinomaunveilsassociationof EGFR mutationswith high Asianancestryandindependentprognostic role of KRAS mutations. Sci Rep 9, 3209 (2019). https://doi.org/10.1038/s41598-019-39965-x

LEITE, C. A. V. G. et al. Receptores tirosina-quinase: implicações terapêuticas no câncer. Rev. Bras. deOncol. Clín, v. 8, n. 29, p. 130-142, 2012.

Lopes, Gabriel Lima; Vattimo, EdoardoFilippo de Queiroz; Castro Junior, Gilberto de. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. Jornal Brasileiro de Pneumologia, v. 41, n. 4, p. 365-375, 2015.

Mountain, Clifton F. The international system for staging lung cancer. In: Seminars in surgical oncology. New York: John Wiley & Sons, Inc., 2000. p. 106-115.

Pacheco, Fernando Azevedo; Paschoal, Marcos Eduardo Machado; Carvalho, Maria da Glória da Costa. Marcadores tumorais no câncer de pulmão: um caminho para a terapia biológica. J Pneumol, v. 28, n. 3, p. 143-49, 2002.

Sedlacek HH. Kinase inhibitors in cancer therapy. A look ahead. Drugs2000;59:435-76.

Shtivelman, Emma et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget, v. 5, n. 6, p. 1392, 2014.

TORRE, Lindsey A.; SIEGEL, Rebecca L.; JEMAL, Ahmedin. Lung cancer statistics. In: Lung cancer and personalized medicine. Springer, Cham, 2016. p. 1-19.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J ThoracOncol. 2011;6(2):244–85.

Wang, Liang et al. Distinct Molecular Mechanisms Analysis of Three Lung Cancer Subtypes Based on Gene Expression Profiles. JournalofComputationalBiology, v. 26, n. 10, p. 1140-1155, 2019.

Zamboni, Mauro. Epidemiologia do câncer do pulmão. J. Pneumologia, São Paulo, v. 28, n. 1, p. 41-47, Jan. 2002.

Downloads

Published

15/05/2022

How to Cite

XAVIER, R. F. .; SILVA, G. H. C. .; GONÇALVES, C. H. E. .; GONÇALVES, D. E. .; MOREIRA, C. G. .; MINERVINO, J. L. C. .; BEZERRA, J. J. . Perspectives in the treatment of lung cancer: analysis of signaling pathways and biomarkers. Research, Society and Development, [S. l.], v. 11, n. 7, p. e5411722903, 2022. DOI: 10.33448/rsd-v11i7.22903. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/22903. Acesso em: 26 nov. 2024.

Issue

Vol. 11 No. 7

Section

Health Sciences

License

Copyright (c) 2022 Ronilson Ferreira Xavier; Gabriel Henrique Cardoso Silva; Charles Henrique Estrela Gonçalves; Daianne Estrela Gonçalves; Cláudio Gonçalves Moreira; João Lucas Caldas Minervino; Jardeson Joaquim Bezerra

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.